1-15 of 261
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart MattersAdvances in ATTR-CM: Evolving Diagnostics and Therapeutics
Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Project Oncology®Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CMPatient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart MattersTreating ATTR-CM Early: A Shift From Reactive to Strategic Care
Recognizing Methamphetamine-Associated PAH: Strategies for Complex Care
Deep Breaths: Updates from CHESTRecognizing Methamphetamine-Associated PAH: Strategies for Complex Care
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart MattersAdvancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
- advertisement
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstractsExploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart MattersUnderstanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart MattersATTR-CM Trials Revisited: A Broader View of Treatment Benefit
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstractsFrom HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
Managing Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
AudioAbstractsManaging Concomitant Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Evolving Care Strategies
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstractsOptimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
- advertisement
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Project Oncology®CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
